Adverse Events of Raltegravir and Dolutegravir
1125  

Adverse Events of Raltegravir and Dolutegravir

To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Methods: All antiretroviral therapy (ART)-naïve and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated concerning treatment modification within the first ...

September 26, 2017
News  
Gates Foundation Invests $40 Million in UK Immunotherapy Company
1146  

Gates Foundation Invests $40 Million in UK Immunotherapy Company

The Bill and Melinda Gates Foundation is to invest up to $40 million in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases. Oxford-based Immunocore has so far concentrated on developing its T-cell receptor medicines to fight cancer, where it ...

September 20, 2017
News  
Atherosclerotic Heart Attack Rate Is 20% Higher Among People With HIV
975  

Atherosclerotic Heart Attack Rate Is 20% Higher Among People With HIV

HIV-positive U.S. residents in the large NA-ACCORD cohort had an atherosclerotic myocardial infarction (MI) rate 20% higher than people in a U.S. general-population cohort, newly published data reveal. This 29,169-person analysis also linked MI risk to lower CD4 count, higher viral load and a host ...

September 01, 2017
News  
Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection
1566  

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

AbbVie’s new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. Glecaprevir/pibrentasvir (Maviret) is expected to be approved ...

July 26, 2017
EATG  News  
Another HIV vaccine efficacy trial will start this year
1147  

Another HIV vaccine efficacy trial will start this year

HVTN 705 vaccine study passes its “go” criteria: due to start this autumn A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, ...

July 26, 2017
AIDSmap  News  
EMA and EUnetHTA step up interaction to align data requirements
1046  

EMA and EUnetHTA step up interaction to align data requirements

A new joint platform for parallel consultation will provide advice to medicine developers and facilitate access to medicines for patients The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) are stepping up their efforts to provide developers of medicines with simultaneous, coordinated advice ...

July 06, 2017
Events  
Indian Scientists Search for a New Way of TB Treatment
957  

Indian Scientists Search for a New Way of TB Treatment

Indian scientists from the University of Delhi have identified molecules that could effectively inhibit TB virus and have published all the results of the study in Scientific Reports journal. The molecules are targeting a gene, important for  the bacterium’s survival. Possibly they may find a new ...

June 22, 2017
News  
Fighting multidrug-resistant tuberculosis in Georgia
1097  

Fighting multidrug-resistant tuberculosis in Georgia

Georgia is currently facing a problem of a high incidence of tuberculosis (TB) and relatively low treatment success rates. Many patients are not followed up properly which contributes to high levels of multidrug-resistant TB: 12 % of new patients are resistant to first line drugs. ...

May 26, 2017
News  
An Activist’s Protocol Review Toolkit
1092  

An Activist’s Protocol Review Toolkit

An Activist's Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols. The three tools contained in the toolkit will help Community Advisory Boards (CABs) think through different aspects of trial design and implementation, organize feedback for the research ...

May 24, 2017
News  
EMA 2016 annual report published
1072  

EMA 2016 annual report published

The European Medicines Agency’s (EMA) 2016 annual report published today focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life. In 2016, the Agency recommended ...

May 15, 2017
News  
Researchers at Illinois gain insights to redirect leading HIV cure strategy
1049  

Researchers at Illinois gain insights to redirect leading HIV cure strategy

Research at the University of Illinois at Urbana-Champaign has provided the first evidence that viruses and hosts share highly similar regulatory sequences in their promoters—the initiation sequences of human genes that code for functional proteins. “To date viral-host networks include protein and mRNA interactions between viruses ...

May 04, 2017
News  
Aidspan publishes new issue of ‘Global Fund Observer’
995  

Aidspan publishes new issue of ‘Global Fund Observer’

Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, published Issue 309 of the “Global Fund Observer.” The newsletter features articles on various topics, including an article on the release of Aidspan’s Asia Pacific report, which provides an overview of ...

April 20, 2017
News  
Genetic study reveals how hepatitis C interacts with humans
1103  

Genetic study reveals how hepatitis C interacts with humans

A big data study of hepatitis C and more than 500 patients with the virus has opened the way for a better understanding of how the virus interacts with its human hosts. Researchers at the University of Oxford have for the first time developed a method ...

April 12, 2017
News